Black Diamond Therapeutics, Inc. (BDTX) 2025年第一季度财报(10-Q)「NASDAQ」.pdf

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549_FORM 10-Q_ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934FOR THE QUARTERLY PERIOD ENDED March 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHA

2、NGEACT OF 1934FOR THE TRANSITION PERIOD FROM _ TO _COMMISSION FILE NUMBER 001-38501_BLACK DIAMOND THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)_Delaware81-4254660(State or other jurisdictionof incorporation or organization)(I.R.S.EmployerIdentification No.)One Main Street,1

3、4th FloorCambridge,Massachusetts(Address of principal executive offices)02142(Zip Code)(617)252-0848(Registrants telephone number,including area code)Not Applicable(Former name,former address and former fiscal year,if changed since last report)Securities registered pursuant to Section 12(b)of the Ac

4、t:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon stock,par value$0.0001BDTXThe Nasdaq Global Select MarketIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the SecuritiesExchange Act of 1934 during

5、 the preceding 12 months(or for such shorter period that the registrant was required to file suchreports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to

6、be submittedpursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period thatthe registrant was required to submit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-acce